Downregulation of the p75 neurotrophin receptor in tissue culture and in vivo, using β-cyclodextrin-adamantane-oligonucleotide conjugates

Antisense and Nucleic Acid Drug Development

Volumn 10, Issue 6, 2000, Pages 469-478

  Epa, W R ^a   Greferath, U ^a   Shafton, A ^a   Rong, P ^a   Delbridge, L M ^a   Bennie, A ^a   Barrett, G L ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMANTANE; ANTISENSE OLIGONUCLEOTIDE; BETA CYCLODEXTRIN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PROTEIN P75;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPLEX FORMATION; DRUG UPTAKE; GENE TARGETING; IN VIVO STUDY; KIDNEY; LIVER; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SPINAL GANGLION; TISSUE CULTURE;

ANIMALIA;

EID: 0034530997     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.1.2000.10.469     Document Type: Article

References (28)

1. Beta-cyclodextrin derivatives as carriers to enhance the antiviral activity of an antisense oligonucleotide directed toward a coronavirus intergenic consensus sequence
2. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice
3. In vivo studies with antisense oligonucleotides
4. Permeation of proteins from the blood into peripheral nerves and ganglia
5. The blood-nerve barrier: Enzymes, transporters and receptors - A comparison with the blood-brain barrier
6. The p75 nerve growth factor receptor mediates survival or death depending on the stage of sensor neuron development
7. The low-affinity nerve growth factor receptor p75(NGFR) mediates death of PC12 cells after nerve growth factor withdrawal
8. In vivo fate of phosphorothioate antisense oligodeoxynucleotides: Predominant uptake by scavenger receptors on endothelial liver cells
9. Reducing p75 nerve growth factor receptor levels using antisense oligonucleotides prevents the loss of axotomized sensory neurons in the dorsal root ganglia of newborn rats
10. Pharmacokinetic properties of several novel oligonucleotide analogs in mice
11. Unexplained peculiarities of the dorsal root ganglion
12. Oligonucleotides as inhibitors of protein synthesis
13. Enhanced downregulation of the p75 nerve growth factor receptor by cholesteryl and bis-cholesteryl antisense oligonucleotides
14. Synthesis, hybridization properties, nuclease stability, and cellular uptake of the oligonucleotide-amino-beta-cyclodextrins and adamantane conjugates
15. Dorsal root ganglia ma be reservoirs of viral infection in multiple sclerosis
16. Alzheimer disease - When and why?
17. Is p75NGFR involved in developmental neural cell death?
18. Induction of apoptosis by the low-affinity NGF receptor
19. Pharmaceutical applications of cclodextrins. 2. In vivo drug deliver
20. Barrier mechanisms in the brain. I. Adult brain
21. Barrier mechanisms in the brain. II. Immature brain
22. 35S-labeled polyphosphorothioate oligodeoxyribonucleotides by use of hydrogen phosphonate chemistry
23. Exploiting the potential of antisense: Beyond phosphorothioate oligodeoxynucleotides
24. Cyclodextrin drug cartier systems
25. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain
26. Localization of oligonucleotides in brain by in situ hybridization
27. Use of cyclodextrin and its derivatives as carriers for oligonucleotide delivery
28. Modulation of oligonucleotide-induced immune stimulation by cyclodextrin analogs